Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Efficacy and Safety of Finasteride Therapy for Androgenetic Alopecia

Efficacy and Safety of Finasteride Therapy for Androgenetic Alopecia EVIDENCE-BASED DERMATOLOGY: REVIEW Efficacy and Safety of Finasteride Therapy for Androgenetic Alopecia A Systematic Review Jose ´ Manuel Mella, MD; Marı ´a Clara Perret, MD; Matı ´as Manzotti, MD; Hugo Norberto Catalano, MD, PhD; Gordon Guyatt, MD, PhD Context: Androgenetic alopecia is the most common form CI, 1.15-2.53]; I , 16%); both results were considered to of alopecia in men. have moderate-quality evidence. The number needed to treat for 1 patient to perceive himself as improved was 5.6 (95% Objective: To determine the efficacy and safety of finas- CI, 4.6-7.0) in the short term and 3.4 (95% CI, 2.6-5.1) in teride therapy for patients with androgenetic alopecia. the long term. Moderate-quality evidence suggested that finasteride therapy increased the mean hair count from base- Data Sources: MEDLINE, EMBASE, CINAHL, Coch- line in comparison to placebo treatment, expressed as a per- rane Registers, and LILACS were searched for random- centage of the initial count in each individual, at short term ized controlled trials reported in any language that evalu- (mean difference [MD], 9.42% [95% CI, 7.95%-10.90%]; ated the efficacy and safety of finasteride therapy in I , 50%) and at long term (MD, 24.3% [95% CI, 17.92%- comparison to treatment with http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

Efficacy and Safety of Finasteride Therapy for Androgenetic Alopecia

Loading next page...
 
/lp/american-medical-association/efficacy-and-safety-of-finasteride-therapy-for-androgenetic-alopecia-piKJmRlPdj
Publisher
American Medical Association
Copyright
Copyright 2010 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/archdermatol.2010.256
pmid
20956649
Publisher site
See Article on Publisher Site

Abstract

EVIDENCE-BASED DERMATOLOGY: REVIEW Efficacy and Safety of Finasteride Therapy for Androgenetic Alopecia A Systematic Review Jose ´ Manuel Mella, MD; Marı ´a Clara Perret, MD; Matı ´as Manzotti, MD; Hugo Norberto Catalano, MD, PhD; Gordon Guyatt, MD, PhD Context: Androgenetic alopecia is the most common form CI, 1.15-2.53]; I , 16%); both results were considered to of alopecia in men. have moderate-quality evidence. The number needed to treat for 1 patient to perceive himself as improved was 5.6 (95% Objective: To determine the efficacy and safety of finas- CI, 4.6-7.0) in the short term and 3.4 (95% CI, 2.6-5.1) in teride therapy for patients with androgenetic alopecia. the long term. Moderate-quality evidence suggested that finasteride therapy increased the mean hair count from base- Data Sources: MEDLINE, EMBASE, CINAHL, Coch- line in comparison to placebo treatment, expressed as a per- rane Registers, and LILACS were searched for random- centage of the initial count in each individual, at short term ized controlled trials reported in any language that evalu- (mean difference [MD], 9.42% [95% CI, 7.95%-10.90%]; ated the efficacy and safety of finasteride therapy in I , 50%) and at long term (MD, 24.3% [95% CI, 17.92%- comparison to treatment with

Journal

JAMA DermatologyAmerican Medical Association

Published: Oct 1, 2010

References